Superior immunogenicity and effectiveness of the 3rd BNT162b2 vaccine dose
Superior immunogenicity and effectiveness of the 3rd BNT162b2 vaccine dose
复制标题
第三剂 BNT162b2 疫苗具有卓越的免疫原性和有效性
DOI：
10.1101/2021.12.19.21268037
复制
发表时间：
2021
影响因子：
3.7
通讯作者：
Y. Kreiss
中科院分区：
文献类型：
--
作者：
Y. Lustig;T. Gonen;Lilac Melzer;M. Gilboa;V. Indenbaum;C. Cohen;S. Amit;H. Jaber;R. Doolman;K. Asraf;Carmit Rubin;R. Fluss;E. Mendelson;L. Freedman;G. Regev;Y. Kreiss
在一项涉及12，413名卫生保健工作者（HCW）的前瞻性队列研究中，我们评估了第三剂BNT 162 b2疫苗的免疫原性、疫苗有效性（VE）和安全性。第三次给药后一个月，与第二次给药后一个月相比，抗RBD-IgG诱导了1.7倍。亲合力从61.1%（95%CI：56.1-66.7）显著增加至96.3%（95%CI：94.2-98.5），导致中和抗体诱导增加6.1倍。线性混合模型表明，第三次给药在HCW[≥]60或有[≥]两种合并症的患者中引起更大的应答，这些患者在第二次给药后的应答较低。第三剂相对于两剂的VE为85.6%（95% CI，79.2-90.1%）。未报告严重不良反应。这些结果表明，第三剂在IgG抗体的数量和质量方面均上级第二剂，并且通过产生高亲和力抗体至健康人群和易感人群之间没有显著差异的水平，安全地增强了对SARS-CoV-2感染的保护。
In a prospective cohort study involving 12,413 Health Care Workers (HCW), we assessed immunogenicity, vaccine-effectiveness (VE) and safety of the third BNT162b2 vaccine dose. One month after third dose, anti-RBD-IgG were induced 1.7-folds compared to one month after the second. A significant increase in avidity from 61.1% (95%CI:56.1-66.7) to 96.3% (95%CI:94.2-98.5) resulted in a 6.1-folds neutralizing antibodies induction. Linear mixed model demonstrated that the third dose elicited a greater response among HCW[≥]60 or those with [≥]two comorbidities who had a lower response following the second dose. VE of the third dose relative to two doses was 85.6% (95% CI, 79.2-90.1%). No serious adverse effects were reported. These results suggest that the third dose is superior to the second dose in both quantity and quality of IgG-antibodies and safely boosts protection from SARS-CoV-2 infection by generating high avidity antibodies to levels that are not significantly different between healthy and vulnerable populations.